Uncoupling protein 2 and aldolase B impact insulin release by modulating mitochondrial function and Ca^{2+} release from the ER

Highlights
- Increased UCP2 expression impairs β-cell function independent of proton leak
- UCP2 induces the expression of AldB, a glycolytic enzyme, in β-cells
- Mitochondrial function and Ca^{2+} release from the ER are dysregulated by AldB
- Knockdown of AldB rescues UCP2-mediated β-cell failure
Uncoupling protein 2 and aldolase B impact insulin release by modulating mitochondrial function and Ca²⁺ release from the ER

Ryota Inoue,¹,² Takahiro Tsuno,¹,² Yu Togashi,² Tomoko Okuyama,² Aoi Sato,¹ Kuniyuki Nishiyama,¹,² Mayu Kyohara,² Jinghe Li,¹,² Setsuko Fukushima,¹ Tatsuya Kin,³ Daisuke Miyashita,² Yusuke Shiba,² Yoshitoshi Atobe,⁴ Hiroshi Kiyonari,⁵ Kana Bando,⁵ A.M. James Shapiro,³ Kengo Funakoshi,⁴ Rohit N. Kulkarni,⁶ Yasuo Terauchi,² and Jun Shirakawa¹,²,⁷,*

SUMMARY

Uncoupling protein 2 (UCP2), a mitochondrial protein, is known to be upregulated in pancreatic islets of patients with type 2 diabetes (T2DM); however, the pathological significance of this increase in UCP2 expression is unclear. In this study, we highlight the molecular link between the increase in UCP2 expression in β-cells and β-cell failure by using genetically engineered mice and human islets. β-cell-specific UCP2-overexpressing transgenic mice (βUCP2Tg) exhibited glucose intolerance and a reduction in insulin secretion. Decreased mitochondrial function and increased aldolase B (AldB) expression through oxidative-stress-mediated pathway were observed in βUCP2Tg islets. AldB, a glycolytic enzyme, was associated with reduced insulin secretion via mitochondrial dysfunction and impaired calcium release from the endoplasmic reticulum (ER). Taken together, our findings provide a new mechanism of β-cell dysfunction by UCP2 and AldB. Targeting the UCP2/AldB axis is a promising approach for the recovery of β-cell function.

INTRODUCTION

Type 2 diabetes mellitus (T2DM) occurs as a consequence of β-cell dysfunction in a background of systemic insulin resistance (Kahn, 2000). Insulin secretion from pancreatic β-cells is tightly regulated to maintain blood glucose levels within a narrow range. Mitochondrial oxidative phosphorylation (OXPHOS) is the predominant source of ATP in β-cells, and patients with mtDNA mutations exhibit β-cell dysfunction and overt diabetes due to reduced ATP production (Erecinska et al., 1992; Gerbitz et al., 1996).

Uncoupling proteins (UCPs) create proton leaks in the mitochondrial inner membrane, which dissipate the proton motive force, thereby bypassing energy conservation by ATP synthase, and the energy is dissipated as heat. UCP1 is specifically expressed in brown adipocytes and is known to play a role in thermogenesis (Nedergaard et al., 2001). Moreover, UCP2, which has 59% amino acid identity to UCP1 in humans, is expressed widely in metabolic tissues, including pancreatic β-cells (Fleury et al., 1997). UCP2 protein levels have been reported to be increased in the islets of individuals with T2DM compared with those from nondiabetic humans (Anello et al., 2005). It remains unclear how UCP2 affects the development of diabetes, yet some research groups have used either UCP2-overexpressing mouse islets or β-cell-specific UCP2-knockout mice (Chan et al., 1999; Produit-Zengaffinen et al., 2007; Robson-Doucette et al., 2011; Zhang et al., 2001). The possibility that UCP2 does not act as an uncoupler has also been suggested (Galetti et al., 2009; Nicholls, 2021).

To clarify the significance of UCP2 expression in pancreatic β-cells in relation to the pathogenesis of T2DM, we investigated the regulatory mechanisms underlying UCP2 expression in β-cells and analyzed the phenotype of mice with a β-cell-specific UCP2-overexpressing transgene (βUCP2Tg). We also focused on the role of aldolase B (AldB) in β-cells, which was the most upregulated gene in islets from βUCP2Tg mice.
RESULTS

UCP2 expression is increased in the islets of mice with T2DM

First, we measured the expression levels of Ucp1, Ucp2, and Ucp3 in islets from C57BL/6J mice (n = 3). N.D.: not detected. (B–G) Ucp2 mRNA levels in mouse islets and β-cell lines.

(B) Islets from IRS2KO and WT mice were incubated with 3.9 or 11.1 mmol/L glucose for 24 h (WT: n = 4, IRS2KO: n = 5).

(C) Islets from db/db and db/+ mice were incubated with 3.9 or 11.1 mmol/L glucose for 24 h (n = 4 per group).

(D) IRS2KO β-cell lines and control β-cell lines were incubated with 25 mmol/L glucose for 24 h (n = 6 per group).

(E) Islets from C57BL/6J mice were incubated with 3.9 or 11.1 mmol/L glucose with or without 30 mmol/L GKA for 24 h (low- and high-glucose group: n = 4, GKA group: n = 2).

(F) Starved islets from C57BL/6J mice were treated with or without 10 nmol/L insulin for 12 h (n = 5 per group).

(G) Islets from C57BL/6J mice were incubated with 2.8, 5.6, or 11.1 mmol/L glucose with or without 20 mmol/L NAC for 24 h (n = 4 per group).

(H) Western blots of UCP2 and α-tubulin in islets from C57BL/6J mice. Islets were incubated with 3.9 or 11.1 mmol/L glucose for 24 h (n = 6 per group). Western blotting was performed by Abby system.

(I) Western blots of UCP2 and α-tubulin in INS1 832/13 cells. Cells were incubated with 2.8 or 16.7 mmol/L glucose for 24 h (n = 6 per group). Data are the means ± SEM *p < 0.05, **p < 0.01. The two-tailed Student’s t test was used in (D), (F), (H), and (I). One-way ANOVA was used in (B), (C), (E), and (G).

Figure 1. UCP2 expression was increased in islets exposed to type 2 diabetes-like conditions

(A) mRNA levels of Ucp1, Ucp2, and Ucp3 in islets from C57BL/6J mice (n = 3). N.D.: not detected.

(B–G) Ucp2 mRNA levels in mouse islets and β-cell lines.
Figure 2. βUCP2Tg mice showed impaired glucose tolerance with reduced insulin secretion
(A) Ucp2 mRNA levels in the islets, livers, and hypothalamus from βUCP2Tg mice and their littermate WT mice (WT: n = 4, βUCP2Tg: n = 5–6).
(B) Blood glucose levels in βUCP2Tg and WT mice (WT: n = 13, βUCP2Tg: n = 21).
(C) OGTT in βUCP2Tg and WT mice (WT: n = 29, βUCP2Tg n = 36, 1.5 g/kg BW glucose).
(D) Body weight changes in βUCP2Tg and WT mice (WT: n = 13, βUCP2Tg: n = 21).
(E) Western blot of UCP2 and α-tubulin in βUCP2Tg and WT islets. Islets were incubated with 11.1 mmol/L glucose for 24 h (n = 3 per group).
(F) Serum insulin levels during the OGTT in βUCP2Tg and WT mice at 0 and 15 min (left panel, WT: n = 7, βUCP2Tg: n = 8, 1.5 g/kg BW glucose) and at 0, 2, and 5 min (right panel, WT: n = 14, βUCP2Tg: n = 17, 2.5 g/kg BW glucose).
(G) Glucose-stimulated insulin secretion (GSIS) in βUCP2Tg and WT islets. Islets were incubated in KRB buffer containing 2.8 or 16.7 mmol/L glucose for 90 min with or without 100 nmol/L liraglutide (n = 5 per group).
(H) Western blot of UCP2 and α-tubulin in MIN6-M9 cells. Cells were infected with Ad-LacZ or Ad-Ucp2 at an MOI of 500 for 48 h (n = 3 per group).
(I) GSIS in MIN6-M9 cells. Cells were infected with Ad-LacZ or Ad-Ucp2 at an MOI of 500 for 48 h and then incubated with 2.8 or 16.7 mmol/L glucose for 90 min (n = 4 per group).
evaluate the effect of glucose signaling on changes in Ucp2 expression, we treated the islets with glucose, a glucokinase activator (GKA) (Figure 1E), or insulin (Figure 1F), and in all conditions, the expression of Ucp2 was increased. Moreover, the upregulation of Ucp2 induced by high glucose concentration was partially inhibited by N-acetylcysteine (NAC), an antioxidant (Figure 1G). We also confirmed the increased protein levels of UCP2 in mouse islets and INS1 β-cells in the presence of high glucose concentrations (Figures 1H and 1I).

Because the activation of glucose signaling by GKA inhibited the apoptosis induced by ER stress (Shirakawa et al., 2013), we examined the effect of ER stress on Ucp2 expression in mouse islets. The expression of Ucp2 in mouse islets was not changed by treatment with thapsigargin, an inducer of ER stress (Figure S1A). We next assessed the effects of insulin receptor signaling on Ucp2 expression. OSI-906, a dual inhibitor of IGF-1 and insulin receptors, had no effect on Ucp2 expression in mouse islets (Figure S1B). Conversely, islet Ucp2 expression was decreased by treatment with Akt inhibitor X, a selective inhibitor of Akt phosphorylation (Figure S1C), or U0126, an ERK inhibitor (Figure S1D). We also explored the effect of potassium channel activity and calcium signaling on Ucp2 expression, which are important in glucose-stimulated insulin secretion, and no changes in Ucp2 expression were observed in mouse islets treated with diazoxide, a potassium channel opener (Figure S1E); nifedipine, an L-type calcium channel blocker; or FK506, a calcineurin inhibitor (Figure S1F). The mammalian target of rapamycin (mTOR) signal is activated by insulin signaling in pancreatic β-cells, but the mTOR inhibitor rapamycin had no effect on islet Ucp2 expression under high glucose conditions (Figure S1G).

These results indicated that the expression of Ucp2 was upregulated via Akt or ERK pathways under diabetes-like pathophysiological conditions, such as hyperglycemia and oxidative stress.

**Overexpression of UCP2 in β-cells impairs insulin secretion**

To investigate the impact of UCP2 upregulation in diabetic β-cells, we generated βUCP2Tg mice. These mice overexpress the full-length Ucp2 gene specifically in pancreatic β-cells under rat insulin promoter activity (Figure S2A). βUCP2Tg mice showed significantly increased Ucp2 expression in islets but not in livers or hypothalamus compared with the corresponding wild-type (WT) mice (Figure 2A). βUCP2Tg mice exhibited significantly impaired glucose tolerance (Figures 2B and 2C). No changes were observed in body weights in βUCP2Tg mice compared with the controls (Figure 2D). We then validated the increased protein levels of UCP2 in islets from βUCP2Tg mice (βUCP2Tg islets) (Figure 2E). Moreover, there was no change in the expression level of Ucp1 in βUCP2Tg islets (Figure S2B), suggesting an absence of compensatory effect between the isoforms. Serum insulin levels were significantly reduced in βUCP2Tg mice at 5 but not 15 min after glucose loading (Figure 2F). The insulinoenic index was decreased in βUCP2Tg mice at 2 and 5 min after glucose loading (Figure S2C). The βUCP2Tg islets showed decreased insulin secretion in response to glucose stimulation (Figure 2G). Conversely, liraglutide, a GLP-1 receptor agonist, enhanced insulin secretion in both mice (Figure 2G). Furthermore, adenovirus-vector-induced expression of Ucp2 reduced insulin secretion in MIN6-M9 cells and human islets (Figures 2H–2J and S2D). The insulin sensitivity in βUCP2Tg mice was similar to that in WT mice (Figure 2K). β-cell mass and β-cell proliferative activity in βUCP2Tg mice were comparable to those in WT animals (Figures S2E and S2F).

**βUCP2Tg islets exhibited abnormalities in mitochondrial morphology and function**

Because UCP2 localizes to the inner mitochondrial membrane, we investigated mitochondrial function in βUCP2Tg islets. The βUCP2Tg islets showed a significant decrease in ATP production in response to glucose stimulation (Figure 3A). Analysis of mitochondrial respiration revealed that mitochondrial basal respiration, maximal respiration, and ATP production were all significantly lower, whereas no change in proton leakage was noted in βUCP2Tg islets (Figures 3B and 3C). Furthermore, adenovirus-vector-induced overexpression of Ucp2 reduced mitochondrial membrane potential in MIN6-M9 cells, suggesting that mitochondrial dysfunction was induced by UCP2 (Figure 3D). We found that the protein level of
The expression of UCP2 and AldB was also detected in human (Figure 3K).

Drp1 of (Figures 3I and 3J). These results indicated that the mitochondrial dysfunction induced by UCP2 enhanced flux in UCP2-overexpressing MIN6-M9 cells, and the mitophagy flux was significantly increased by UCP2.

UCP2Tg islets showed increased expression of UCP2 and AldB in increased in b for both UCP2 and AldB was mainly localized in mitochondria (Gerst et al., 2018). The protein levels of AldB were also increased in expression of which has been reported to be negatively associated with insulin secretion in human islets and S3A). The most upregulated gene in (Figure 3H). It has been reported that upregulated mitophagy flux reduces the expression of PARKIN due to increased protein turnover in the MIN6 cell line (Lemasters et al., 1998). Mitophagy, which refers to selective mitochondrial autophagy, is critical for the removal of damaged mitochondria (Lemasters et al., 1998). In UCP2Tg islets, the protein expression levels of PARKIN and PINK1, which are known to be mitophagy-related proteins (Narendra et al., 2008), were significantly decreased (Figure 3H). It has been reported that upregulated mitophagy flux reduces the expression of PARKIN due to increased protein turnover in the MIN6 β-cell line (Sidarala et al., 2020). We measured the mitophagy flux in UCP2-overexpressing MIN6-M9 cells, and the mitophagy flux was significantly increased by UCP2 (Figures 3I and 3J). These results indicated that the mitochondrial dysfunction induced by UCP2 enhanced mitophagy, resulting in decreased mitophagy-related protein expression. Moreover, the expression levels of Drp1, Opa1, and Mfn1, which are related to mitochondrial fission and fusion (Zorzano et al., 2010), and Tfam, a mitochondrial transcription factor (Ekstrand et al., 2004), remained unchanged in UCP2Tg islets (Figure 3K).

**Aldolase B is induced by UCP2 in pancreatic β-cells**

To identify the target genes of UCP2 in pancreatic β-cells, we performed gene expression microarray analysis in UCP2Tg islets. We identified 13 upregulated genes (≥1.5-fold, p < 0.05) and one downregulated gene (≤0.67-fold, p < 0.05) in UCP2Tg islets and validated the mRNA levels by qPCR (Figures 4A–4C and S3A). The most upregulated gene in UCP2Tg islets was aldolase B (AldB) (Figures 4C and 4D), the expression of which has been reported to be negatively associated with insulin secretion in human islets (Gerst et al., 2018). The protein levels of AldB were also increased in UCP2Tg islets (Figure 4E). Among the aldolase subtypes, the expression of aldolase A (AldA) was the highest in the WT islets, whereas the UCP2Tg islets showed higher expression levels of AldB than AldA (Figure S3B). Immunofluorescence for both UCP2 and AldB was mainly localized in β-cells, and the signal intensities for these proteins were increased in UCP2Tg islets (Figures 4F and 4G). Stained emission depletion (STED) microscopy also showed increased expression of UCP2 and AldB in UCP2Tg β-cells (Figure S3C). We confirmed that adenovirus-vector-induced expression of Ucp2 in mouse islets increased AldB expression (Figure 4H). The expression of UCP2 and AldB was also detected in human β-cells (Figure S3D).

**AldB expression was regulated by high glucose and free fatty acids in β-cells**

Next, we investigated the regulatory mechanisms of AldB expression in β-cells. The protein level of AldB in INS1 β-cells was increased by stimulation with glucose (Figure S5A) or palmitate (Figure S5B). Fluorescent immunostaining showed that the signal intensities for AldB were increased in human β-cells by high glucose concentrations (Figures 5C and SD). Consistently, the islets from hyperglycemic IRS2KO mice (Figure 5E) and db/db mice (Figure 5F) showed a tendency toward increased AldB expression, similar to the case...
Figure 4. Aldolase B was increased in βUCP2Tg β-cells

(A–C) DNA microarray in βUCP2Tg and WT islets (n = 4 per group). Islets were incubated with 11.1 mmol/L glucose for 8 h.

(A) Scatterplot.

(B) Volcano plot.

(C) Heatmap. The graph shows the gene symbols, fold-change (βUCP2Tg versus WT), and p value.

| Gene symbol | Fold change [Tg] vs [WT] | p-value |
|-------------|--------------------------|---------|
| AldB        | 76.7                     | <0.01   |
| Ucp2        | 76.3                     | <0.01   |
| Ucp3        | 44.3                     | <0.01   |
| Yipf7       | 19.7                     | <0.01   |
| Sp8         | 19.5                     | 0.04    |
| Ptger3      | 8.8                      | 0.04    |
| Kctd8       | 7.5                      | <0.01   |
| Tenm4       | 4.1                      | 0.04    |
| Togaram2    | 3.7                      | 0.04    |
| Cidec       | 3.4                      | 0.04    |
| Gm34542     | 3.3                      | <0.01   |
| Tmie        | 3.0                      | 0.03    |
| Tmed6       | 2.4                      | 0.04    |
| G2e3        | -1.9                     | 0.04    |
for Ucp2 expression. Treatment with insulin, however, did not affect the expression of Aldb in mouse islets (Figure S4A). Modulation of ER stress by treatment with thapsigargin (Figure S4G) increased the expression of Aldb in mouse islets, unlike the case for UCP2, suggesting that Aldb expression could also be induced by cellular stressors. As shown in a previous report (Ma et al., 2007), diazoxide increased Aldb expression in mouse islets (Figure S4B). Meanwhile, neither inhibition of L-type calcium channels by nifedipine nor inhibition of calcineurin by FK-506 affected Aldb expression (Figure S4C). Regarding insulin receptor signaling, treatment with OSI-906, an IR/IGF1R dual inhibitor, decreased Aldb expression, whereas treatment with an Akt inhibitor increased Aldb expression in the presence of GKA (Figures S4D and S4E). In vitro, OSI-906 did not inhibit insulin signaling in β-cells (Shirakawa et al., 2014), which could explain the difference in Aldb expression between OSI-906 and Akt inhibitor.

**UCP2-mediated proton leakage did not affect insulin secretion in βUCP2Tg islets**

Genipin reportedly inhibited UCP2-mediated proton leakage in mouse islets (Zhang et al., 2006). The expression of Aldb was not suppressed by genipin in βUCP2Tg islets (Figure 5H). Therefore, we evaluated the contribution of proton leakage induced by UCP2 to the impairment of insulin secretion in βUCP2Tg β-cells by using genipin. Because genipin did not affect GSIS in either WT or βUCP2Tg islets (Figure 5I), uncoupling by UCP2 did not seem to be associated with decreased insulin secretion in βUCP2Tg islets. We further investigated the effect of genipin on mitochondrial function (Figures 5J–5L). Mitochondrial respiration after treatment with glucose or FCCP and ATP production were decreased by adenoviral expression of Ucp2 in mouse islets (Figures 5J–5L). Proton leakage was not changed by adenoviral overexpression of Ucp2 in mouse islets (Figure 5L), similar to βUCP2Tg islets (Figure 3C). Moreover, genipin did not affect mitochondrial respiration, proton leakage, or ATP production in UCP2-overexpressing islets (Figures 5K and 5L). From these results, UCP2 induced β-cell dysfunction without any changes of proton leakage.

**UCP2 regulated Aldb expression through the oxidative-stress-mediated pathway**

We further investigated the regulatory mechanism of Aldb expression by UCP2. Previous reports have shown that Aldb is the target gene of hepatocyte nuclear factor 4α (HNF4α) in INS1 rat β-cell lines (Wang et al., 2000). We analyzed the 2-kb sequences of the murine and human Aldb promoter regions and identified a putative HNF4α binding site (Figure 6A). We also found that the expression of Hnf4α was upregulated in βUCP2Tg islets (Figure 6B) and in WT islets exposed to high glucose (Figure 6C). The expression of Nrf2 and Sod2, which are oxidative-stress-related genes, was increased in βUCP2Tg islets (Figure 6D). The signal intensity of mtSOX Deep Red, which emits fluorescence in response to mitochondrial superoxide, was increased by overexpression of UCP2 in MIN6-M9 cells (Figure 6E). We treated UCP2-overexpressing islets with NAC to evaluate the involvement of oxidative stress, and increased expression of Nrf2 and SOD2 were abolished by NAC (Figure 6F). Although the protein levels of HNF4α were not significantly changed by overexpression of UCP2 in islets, the fluorescent intensity of HNF4α in the nucleus was increased by highly expressed UCP2 in MIN6-M9 cells, and this effect was reversed by NAC treatment (Figure 6G). We also investigated whether ER stress contributed to Aldb induction by UCP2 because thapsigargin increased the expression of Aldb in mouse islets (Figure 5G). As shown in Figure S1A, Ucp2 expression was not induced by thapsigargin, and the expression of Ddit3, Atf4, Atf6, and Ern1, which are ER-stress-related genes, was not changed in BUCP2Tg islets (Figure 6H). Furthermore, adenoviral expression of Aldb in islets did not affect the expression levels of ER-stress-related genes (Figure 6I). Based on these results, oxidative stress, but not ER stress, was involved in the increase in Aldb expression in βUCP2Tg β-cells.

We also analyzed whether Aldb participates in β-cell function. Importantly, adenovirus-vector-induced expression of Aldb in MIN6-M9 cells decreased GSIS (Figures 6J and 6K). To investigate whether UCP2-induced Aldb
Figure 5. The regulation of AldB expression in islets and the effect of proton leakage by UCP2 on insulin secretion

(A and B) Western blot of AldB and α-tubulin in INS1 β-cells.
(A) Cells were incubated with 2.8 or 16.7 mmol/L glucose for 24 h (n = 3 per group).
(B) Cells were treated with BSA or 0.5 mmol/L palmitate for 24 h (n = 3 per group).
(C and D) Immunostaining of human islets. Islets were incubated with 5.6 or 16.7 mmol/L glucose for 48 h. Insulin is stained green, AldB is stained red, and DAPI is stained blue. The scale bar represents 50 μm.
(D) Graph shows the intensity of AldB staining in insulin-positive β-cells (n = 5 islets from one donor).
(E and F) AldB mRNA levels in islets from IRS2KO and WT mice (E, WT: n = 4, IRS2KO: n = 2–4) and db/db and db/+ mice (F, db/+: n = two to four, db/db: n = 4). Islets were incubated with 3.9 or 11.1 mmol/L glucose for 24 h.
(G) AldB mRNA levels in islets from WT and βUCP2Tg mice. Islets were incubated with 5.6 mmol/L glucose with or without 1 μmol/L thapsigargin for 24 h (n = 4 per group).
(H) AldB mRNA levels in islets from βUCP2Tg mice. Islets were incubated with 5.6 mmol/L glucose with or without 1 μmol/L genipin for 24 h (n = 3 per group).
(I) GSIS in islets from WT and βUCP2Tg mice. Islets were incubated in KRB buffer containing 2.8 and 16.7 mmol/L glucose for 90 min with or without 5 μmol/L genipin (n = 3 per group).
(J) Western blot of UCP2 and β-actin in mouse islets. Islets were infected with Ad-LacZ or Ad-Ucp2 at an MOI of 1 × 10^4 and cultured in the RPMI1640 medium containing 5.6 mmol/L glucose for 24 h.
(K and L) Oxygen consumption rate in islets from C57BL/6J mice. Islets were infected with Ad-LacZ or Ad-Ucp2 at an MOI of 1 × 10^4 and cultured in the RPMI1640 medium containing 5.6 mmol/L glucose in the presence or absence of 5 μmol/L genipin for 24 h.
(K) The asterisk indicates a significant difference in comparison with the Ad-Ucp2 + DMSO group.
(L) The graph shows nonmitochondrial oxygen consumption, basal respiration, maximal respiration, proton leakage, ATP production, and spare respiratory capacity. Data are the means ± SEM *p < 0.05, **p < 0.01. N.S.: not significant. The two-tailed Student’s t test was used in (A), (B), (D), (H), and (J). One-way ANOVA was used in (E–G), (I), (K), and (L).
Figure 6. AldB was induced by UCP2 in an oxidative stress-mediated pathway
(A) Schematic of the Hnf4α-binding motif in the AldB promoter region (left panel: mouse, right panel: human).
(B) Hnf4α mRNA levels in βUCP2Tg and WT islets (n = 3 per group). Islets were incubated with 11.1 mmol/L glucose for 24 h.
(C) Hnf4α mRNA levels in mouse islets. Islets from C57BL6/J mice were incubated with 3.9 or 11.1 mmol/L glucose for 24 h (n = 3 per group).
(D) Nrf2 and Sod2 mRNA levels in βUCP2Tg and WT islets. Islets were incubated with 5.6 mmol/L glucose for 24 h (n = 3 per group).
(E) Mitochondrial superoxide levels in MIN6-M9 cells. Cells were infected with Ad-LacZ or Ad-AldB at an MOI of 500 for 48 h. The graph shows the intensities of mtSOX Deep Red Dye in MIN6-M9 cells. The scale bar indicates 100 µm.
expression is involved in the impaired insulin secretion in βUCP2Tg mice, we conducted AldB-knockdown experiments by using an adenovirus vector that expressed sh-RNA for AldB. Sh-AldB reduced the AldB mRNA levels in βUCP2Tg islets by approximately 50% (Figure 6L). The knockdown of AldB restored GSIS in βUCP2Tg islets (Figure 6M); therefore, this result indicated that AldB expression was crucial in impaired insulin secretion in βUCP2Tg mice.

Collectively, in stressed β-cells under diabetes, mitochondrial dysfunction caused by elevated UCP2 induced oxidative stress, resulting in activation of HNF4α and thus leading to the elevation of AldB expression. AldB in turn was involved in the impaired insulin secretion caused by UCP2 upregulation.

AldB expression impaired mitochondrial function in β-cells

Next, we investigated the involvement of AldB in the mitochondrial dysfunction observed in βUCP2Tg islets. Forced expression of AldB, as well as Ucp2, in MIN6-M9 cells reduced the mitochondrial membrane potential (Figure 7A). Overexpression of AldB in mouse islets decreased the expression of mitochondrial OXPHOS proteins, complex 2 and complex 4, PARKIN and VDAC (Figures 7B and 7C). We also confirmed that adenovirus-vector-induced AldB expression in islets had no effect on Ucp2 expression (Figure 7D). Methylglyoxal, a major precursor of advanced glycation end products, was reportedly induced by overexpression of AldB and involved in mitochondrial dysfunction in pancreatic β-cells (Bo et al., 2016; Liu et al., 2012). We found increased levels of methylglyoxal in βUCP2Tg islets (Figure 7E). Importantly, knockdown of AldB ameliorated the impairment of mitochondrial respiration induced by overexpression of UCP2 in islets (Figures 7F and 7G). These results indicated that mitochondrial dysfunction in βUCP2Tg islets was mediated, at least in part, by altered AldB expression.

UCP2 and AldB reduce insulin secretion through dysregulation of Ca2+ release from the ER in β-cells

Li et al. reported that the aldolase enzyme inhibits a TRPV4 channel to restrict Ca2+ release from the ER under glucose starvation conditions in mouse embryonic fibroblasts (Li et al., 2019). Therefore, we investigated the roles of UCP2 and AldB in Ca2+ release from the ER in β-cells. We confirmed the expression of Trpv2 and Trpv4 in mouse islets (Figure 8A). HC 067047, a selective TRPV4 inhibitor, decreased GSIS in WT islets but not in βUCP2Tg islets (Figure 8B). Fasiglifam (TAK-875), a GPR40 agonist, has been shown to enhance insulin secretion from β-cells through inositol trisphosphate (IP3)-mediated Ca2+ release from the ER (Nolan et al., 2006). In our study, fasiglifam-induced enhancement of insulin secretion was attenuated in βUCP2Tg islets (Figure 8C). These results suggested that UCP2 participated in the regulation of Ca2+ release from the ER in pancreatic β-cells.

We assessed intracellular Ca2+ influx in βUCP2Tg islets. The increase in intracellular Ca2+ by glucose was attenuated in βUCP2Tg islets compared with islets from WT mice (Figures 8D–8F). The fasiglifam-induced increase in intracellular Ca2+, after depletion of extracellular Ca2+ levels, was completely blunted in βUCP2Tg islets, indicating that Ca2+ release from the ER by fasiglifam was attenuated in βUCP2Tg islets (Figures 8G and 8H). Furthermore, adenovirus-vector-induced expression of AldB in mouse islets also resulted in impaired Ca2+ influx in response to glucose or fasiglifam (Figures 8I–8L). These results indicated that overexpression of UCP2 and the consequent induction of AldB expression in mouse islets...
resulted in impaired Ca$^{2+}$ release from the ER and reduced insulin secretion from pancreatic islets. The knockdown of AldB ameliorated the dysregulation of glucose-stimulated intracellular Ca$^{2+}$ influx caused by UCP2 overexpression in INS1 $\beta$-cell lines (Figures 8M and 8N). We further evaluated the Ca$^{2+}$ concentration in the ER using the FRET-based probe D1ER cameleon (Palmer et al., 2004). The ER Ca$^{2+}$ concentration in control INS1 cells slightly increased after high glucose exposure, whereas UCP2-overexpressing INS1 cells exhibited decreased ER Ca$^{2+}$ (Figures 8O and 8P). We also found that the reduction in Ca$^{2+}$ concentration in the ER after fasiglifam stimulation was not recognized by overexpression of UCP2 in INS1 $\beta$-cell lines (Figures 8O and 8P). Although the expression levels of the Ca$^{2+}$-binding ER protein Calr were decreased in $\beta$UCP2Tg islets, there were no changes in the mRNA expression of the Ca$^{2+}$-ATPase pump Atp2a2, which encodes the SERCA2 protein involved in ER Ca$^{2+}$ influx or the ER Ca$^{2+}$ efflux channel Itpr1 (Figure 8Q). The protein levels of SERCA2 also showed no changes in $\beta$UCP2Tg islets (Figure 8R). Altogether, UCP2-mediated AldB expression might induce the dysregulation of Ca$^{2+}$ release from the ER in pancreatic $\beta$-cells.

Figure 7. AldB impaired mitochondrial function in $\beta$-cells

(A) Mitochondrial membrane potential in MIN6-M9 cells. Cells were infected with Ad-LacZ or Ad-AldB at an MOI of 500 for 48 h. The graph shows the intensities of MT-1 dye in MIN6-M9 cells. The scale bar indicates 100 $\mu$m.

(B and C) Western blots of mitochondrial OXPHOS proteins and $\alpha$-tubulin (B, $n = 3$ per group) and mitophagy-associated proteins and $\alpha$-tubulin (C, $n = 3$ per group) in islets from C57BL/6J mice. Islets were infected with Ad-LacZ or Ad-AldB at 3 $\times$ 10$^6$ MOI in the presence of 5.6 mmol/L glucose for 48 h.

(D) Ucp2 mRNA levels in islets from C57BL/6J mice. Islets were infected with Ad-LacZ or Ad-AldB at an MOI of 3 $\times$ 10$^6$ in the presence of 5.6 mmol/L glucose for 48 h ($n = 3$ per group).

(E) Methylglyoxal levels in $\beta$UCP2Tg and WT islets ($n = 3$ per group). Islets were incubated with 11.1 mmol/L glucose for 24 h.

(F and G) Oxygen consumption rate in islets from C57BL/6J mice. Islets were infected with (1) Ad-LacZ + Sh-Scramble ($n = 3$), (2) Ad-Ucp2 + Sh-Scramble ($n = 3$), or (3) Ad-Ucp2 + Sh-AldB ($n = 3$) at an MOI of 1 $\times$ 10$^6$ in the presence of 5.6 mmol/L glucose for 24 h. The asterisk indicates a significant difference in comparison with the Ad-Ucp2 + Sh-Scramble group.

(G) The graph shows nonmitochondrial oxygen consumption, basal respiration, maximal respiration, proton leakage, ATP production, and spare respiratory capacity. Data are the means ± SEM $*p < 0.05$, **$p < 0.01$. N.S.: not significant. The two-tailed Student’s t test was used in (A–E). One-way ANOVA was used in (F) and (G).
DISCUSSION

In this study, we report that an increase in UCP2 expression in pancreatic β-cells induced AldB expression, which in turn impaired insulin secretion by promoting mitochondrial dysfunction and impaired Ca²⁺ release from the ER (Figure 8S).

The induction of UCP2 by high glucose or oxidative stress is consistent with several independent reports that used INS-1 β-cells, rat islets, and human islets (Brown et al., 2002; Krauss et al., 2003; Li et al., 2009; Medvedev et al., 2002; Pi et al., 2009). In the present study, we report that Akt and ERK, which are activated by glucose, are also involved in UCP2 expression in β-cells. Meanwhile, UCP2 has been shown to be upregulated by glucotoxicity in GLUTag cells, an intestinal L-cell model, and to reduce Glp-1 secretion from GLUTag cells, suggesting that UCP2 contributes to the pathogenesis of T2DM not only in β-cells (Urbano et al., 2016). Further studies are required to clarify the factors that determine UCP2 expression during the development of diabetes.

The impact of UCP2 overexpression in islets on insulin secretion in vitro remains controversial (Chan et al., 1999; Produkt-Zengaffinen et al., 2007). In the current study, BUCP2Tg mice exhibited reduced insulin secretion early (5 min) after glucose loading but not at later time points (e.g., 15 min). Thus, UCP2 might be important in the early secretory response to glucose. The results of Ca²⁺ imaging also showed that early elevation of intracellular Ca²⁺ influx after glucose stimulation (e.g., 20 s) was attenuated in BUCP2Tg islets. We also explored the effect of the GLP-1 agonist liraglutide on GSIS in BUCP2Tg islets. GLP-1R signaling increases intracellular Ca²⁺ levels, which activate protein kinase A (PKA) and Epac2, resulting in enhanced insulin secretion in β-cells (Holst, 2007). Our data showed that liraglutide increased insulin secretion in BUCP2Tg islets as well as WT islets. Therefore, it was considered that the enhancement of insulin secretion by liraglutide was not diminished in BUCP2Tg islets.

Dilatation of the mitochondria and decreased expression of OXPHOS proteins in the mitochondria were observed in BUCP2Tg β-cells in association with reduced ATP production. Because mitochondrial respiratory was impaired without any change in proton leakage in BUCP2Tg islets, the deterioration of the electron transport chain may affect the result rather than the uncoupling. It has been shown that mitochondrial complex protein was reduced in β-cells from diabetic mice (Brown et al., 2021; Haythorne et al., 2019). Haythorne et al. also demonstrated that the protein levels of NDUFB8 were decreased in islets from diabetic
βV59M mice, but its mRNA levels were not changed, thus the downregulation of NDUFB8 protein may occur at the posttranslational level under diabetic conditions. These reports were consistent with our data, where NDUFB8 protein levels were decreased with no changes in mRNA levels in βUCP2Tg islets.

Dilatation of the mitochondria in β-cells has also been observed in diabetic db/db mice (Lo et al., 2010). Although the protein level of PARKIN, an E3 ubiquitin ligase that plays a crucial role in mitophagy, was decreased in BUCP2Tg islets, mitophagy flux was increased. The deletion of PARKIN in pancreatic β-cells did not affect insulin secretion (Corsa et al., 2019). From these findings, it was considered that altered mitophagy-related protein levels in βUCP2Tg islets did not contribute to impaired insulin secretion and that decreased PARKIN expression was caused by the adaptive response of mitophagy and the consumption of PARKIN proteins.

We focused on the role of AldB in β-cells because its expression level was markedly upregulated in βUCP2Tg islets. Notably, the expression of both UCP2 and AldB has been reported to be increased in the islets of T2DM donors (Anello et al., 2005; Gerst et al., 2018). The expression of AldB in human islets has been reported to be negatively associated with insulin secretion in subjects with T2DM (Gerst et al., 2018). Indeed, the expression of AldB was increased in islets from diabetic db/db and IRS2KO mice, and overexpression of AldB attenuated insulin secretion in this study. We also showed an increase in the expression of AldB in human islets in response to high glucose.

We showed that oxidative stress and HNF4α might be involved in AldB transcription. HNF4α is a nuclear receptor (Nammo et al., 2008), and its binding to DNA is inhibited by AICAR, an activator of AMPK (Hong et al., 2003). The expression of downstream genes of HNF4α was suppressed by reduced nuclear localization of HNF4α in human hepatoma cells (Chandra et al., 2011). Therefore, in β-cells from βUCP2Tg mice, inactivation of AMPK by oxidative stress possibly increased the DNA binding of HNF4α and the nuclear translocation of HNF4α, which resulted in upregulation of AldB transcription. Dephosphorylation of AMPK is reportedly induced by oxidative stress in C2C12 mouse myoblast cell lines (Jiang et al., 2021). The intensity of mtSOX Deep Red, which is an indicator of mitochondrial oxidative stress, and NRF2 and SOD2 expression were increased by adenoviral expression of Ucp2 in MIN6-M9 cells or islets. Thus, the excessive UCP2 induced by glucose-induced oxidative stress might further potentiate oxidative stress that leads to AldB expression. A previous report showed the protective effect of UCP2 against oxidative stress in β-cells (Li et al., 2017). However, they also showed that superoxide levels at both 11 mmol/L and 30 mmol/L glucose tended to be increased in UCP2-overexpressing islets. Their data indicate that oxidative stress is induced by UCP2 and are consistent with our data demonstrating the upregulation of NRF2 and SOD2 in βUCP2Tg islets.

Although it was reported that activation of NRF2 promoted mitochondrial biogenesis and insulin secretion in β-cells (Kumar et al., 2018; Yagishita et al., 2014), our UCP2 transgenic mice did not show any increase in insulin secretion. It was unclear whether the increased expression of NRF2 was involved in the phenotype of UCP2 transgenic mice, but this NRF2 upregulation was considered insufficient to restore the decreased insulin secretion in βUCP2Tg mice. Overexpression of AldB in islets reduced the mitochondrial protein levels of OXPHOS, VDAC, and PARKIN, suggesting the involvement of AldB in mitochondrial dysfunction in βUCP2Tg islets. In fact, the increase in AldB expression in MIN6-M9 cells resulted in decreased mitochondrial membrane potential. In previous reports, knockdown of AldB in endothelial cells ameliorated the high glucose-induced accumulation of methylglyoxal (Liu et al., 2012), which is known to induce mitochondrial dysfunction (Bo et al., 2016). AldB is the most upregulated protein in the islets of diabetic βV59M mice, and pathway analysis of the transcriptome data revealed a downregulation of OXPHOS in the mitochondria (Haythorne et al., 2019). Fructose 1,6-bisphosphatase 1 (FBP1), a protein that interacts with AldB, is upregulated in the β-cells of T2DM mice, and inhibition of FBP1 improves insulin secretion (Zhang et al., 2010). Taken together, AldB expression may mediate mitochondrial dysfunction, and decreased insulin secretion was observed in βUCP2Tg mice.

Our results indicated that UCP2 and AldB impaired Ca²⁺ release from the ER in β-cells. Moreover, in mouse embryonic fibroblasts, aldolase binds to the TRPV channel under glucose starvation conditions, following activation of AMPK phosphorylation (Li et al., 2019). Because the effects of a selective TRPV4 inhibitor or fasiglifam on insulin secretion and Ca²⁺ influx are blunted in islets overexpressing UCP2 or AldB, it is possible that UCP2 or AldB inhibits TRPV channel activity and Ca²⁺ release from the ER in pancreatic
β-cells. The interaction of aldolase and TRPV4 channels has been shown (Li et al., 2019). Hence, AldB might modulate the activity of TRPV4 channels. Because the intracellular Ca\(^{2+}\) influx through TRPV4 channels reportedly induced IP3-mediated Ca\(^{2+}\) release from the ER in endothelial cells (Heathcote et al., 2019), the interaction of TRPV4 and AldB might affect insulin secretion in βUCP2Tg β-cells through IP3-mediated Ca\(^{2+}\) release. Ca\(^{2+}\) release from the ER is also mediated by ryanodine receptors (RyR), and pharmacological inhibition of RyR reduces GSIS (Llanos et al., 2015). Ca\(^{2+}\) release from the ER induced by GLP-1R signaling is blocked by the inhibition of RyR but not by the IP3 receptor antagonist in mouse islets and INS1 β-cell lines (Kang et al., 2001; Kim et al., 2008). Our data showed that enhancement of insulin secretion by liraglutide was preserved in βUCP2Tg islets. Therefore, it was considered that RyR-mediated Ca\(^{2+}\) release from the ER was not involved in the decreased insulin secretion in βUCP2Tg β-cells.

GPR40 agonists reportedly enhanced GSIS through IP3-mediated Ca\(^{2+}\) release from the ER and diacylglycerol (DAG)-mediated activation of protein kinase C (PKC) (Yamada et al., 2016). Because the Ca\(^{2+}\) concentration in the ER after stimulation with the GPR40 agonist was not decreased in UCP2-overexpressing INS1 cells, IP3-mediated Ca\(^{2+}\) efflux from the ER was impaired by excessive UCP2. We also found that the Ca\(^{2+}\) concentration in the ER was decreased after glucose stimulation by overexpression of UCP2 in INS1 cells. Because methylglyoxal has been shown to impair the activity of SERCA, a calcium pump in the ER, without any changes of protein levels of SERCA (Zizkova et al., 2018), increased methylglyoxal in βUCP2Tg islets might decrease ER Ca\(^{2+}\) uptake through SERCA. In MIN6 mouse β-cell lines, Ca\(^{2+}\) uptake through SERCA after high glucose stimulation was inhibited by oligomycin, an inhibitor of ATP synthase (Moore et al., 2011), thus the reduction in ATP production in βUCP2Tg islets might affect SERCA activity. Because UCP2 was also shown to act as a Ca\(^{2+}\) uniporter in mitochondria (Koshenov et al., 2020; Trenker et al., 2007), the decrease in the ER Ca\(^{2+}\) concentration after glucose stimulation in UCP2-overexpressing INS1 cells might be caused by increased Ca\(^{2+}\) uptake through UCP2.

We also showed decreased expression of Calr in βUCP2Tg islets. Knockdown of calreticulin in MEFs reduced Ca\(^{2+}\) storage in the ER and impaired IP3-dependent Ca\(^{2+}\) release from the ER (Messaeli et al., 2019). However, the basal Ca\(^{2+}\) concentration in the ER was not changed by UCP2 overexpression in INS1 cells. Because increased calreticulin was reported to inhibit Ca\(^{2+}\) release from the ER because of its high affinity for Ca\(^{2+}\) in C. elegans (Burkewitz et al., 2020), the reduced Calr expression in βUCP2Tg islets might be the adaptive response against the impairment of Ca\(^{2+}\) release from the ER. Taken together, our data suggest that the impairment of Ca\(^{2+}\) release from the ER reduces GSIS in βUCP2Tg β-cells.

Given the role of UCP2 in Ca\(^{2+}\) uptake by mitochondria in HeLa cells (Madreiter-Sokolowski et al., 2016), it is possible that impaired Ca\(^{2+}\) influx in βUCP2Tg β-cells is, at least in part, due to an upregulation of mitochondrial Ca\(^{2+}\) uptake. Whether UCP2 has a role as a classic uncoupling protein, such as UCP1, is controversial (Nicholls, 2016). A previous report showed that overexpression of UCP2 does not reduce the mitochondrial membrane potential in rat INS-1 β-cells, suggesting that UCP2 does not act as an uncoupler (Galetti et al., 2009). Indeed, proton leakage in βUCP2Tg islets was not changed compared with that in WT islets. UCP2 has a half-life of 30 min, whereas the half-life of UCP1 is 30 h (Rousset et al., 2007). This difference in half-life among UCP proteins also indicates distinct physiological functions of UCP2. A previous report characterized UCP2 as a metabolite transporter capable of reducing glucose oxidation in mitochondria (Vozza et al., 2014). Our data also demonstrated a reduction in ATP production and reduced mitochondrial respiration in βUCP2Tg islets. Because decreased GSIS, reduced mitochondrial respiration, and impairment of Ca\(^{2+}\) flux by excessive UCP2 in β-cells were ameliorated by AldB knockdown, UCP2-induced AldB contributed to the β-cell dysfunction of βUCP2Tg mice. In particular, AldB-mediated intracellular Ca\(^{2+}\) regulation by UCP2 in our study may provide clues to the novel pathologic mechanisms underlying β-cell failure.

In summary, we provide evidence that the upregulation of UCP2 in stressed β-cells under diabetes decreased insulin secretion due to mitochondrial dysfunction and impairment of Ca\(^{2+}\) release from the ER. Therefore, inhibition of UCP2 or AldB might be a promising therapeutic strategy to improve insulin secretion in patients with diabetes.

**Limitations of the study**

Our study demonstrates the molecular role of UCP2 and AldB as regulators of insulin secretion in β-cells. We have demonstrated that UCP2 induces AldB expression and suppresses insulin release via dysfunction in mitochondria or Ca\(^{2+}\) release from the ER. Although we showed the requirement of AldB for impaired
insulin secretion in UCP2-overexpressing β-cells in in vitro or ex vivo experiments, it was not evaluated in vivo. An inducible β-cell-specific AldB conditional knockout model will be a convincing tool to clarify this issue. This study highlights the expression and roles of UCP2 and AldB in human islets. To confirm the pathological or therapeutic significance of these two genes, a study using islets from donors with type 2 diabetes needs to be performed. Due to the unavailability and the extensive phenotypic diversity in type 2 diabetes islets, further studies will be needed.

**STAR METHODS**
Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Mice
  - Cell lines and adenovirus
  - Human islet studies
- **METHOD DETAILS**
  - Immunoblotting and Abby western protein analysis
  - qPCR and microarray analysis
  - Immunostaining studies
  - Electron microscopy
  - Mouse studies
  - Islet studies
  - Mitochondrial respiration in islets
  - Assay of mitochondrial membrane potential, mitophagy flux and oxidative stress
  - Methylglyoxal assay in mouse islets
  - Intracellular Ca2+ measurement
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

**SUPPLEMENTAL INFORMATION**
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2022.104603.

**ACKNOWLEDGMENTS**
We thank Professor Patrick MacDonald PhD (Alberta Diabetes Institute, University of Alberta) for providing the human islets from Alberta Diabetes Institute IsletCore. We thank Dr. Christopher Newgard (Duke University) for providing the INS-1 cells (832/13 cells) and Dr. Susumu Seino (Kobe University) for providing the MIN6-M9 cells. We also thank Mitsuyo Kaji and Eri Sakamoto (Yokohama City University) and Chizu Nishiyama (Gunma University) for their excellent technical assistance and Misa Katayama (Yokohama City University) and Fuyumi Murai (Gunma University) for their excellent secretarial assistance.

J.S. acknowledges support from a Grant-in-Aid for Scientific Research (C) 20K08866 from MEXT of Japan, the Japan IDDM network, Japan Diabetes Foundation, Uehara Memorial Foundation, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, Kamome Memorial Foundation of Yokohama City University, Naito Foundation, Astellas Foundation for Research on Metabolic Disorders, and A*STAR—AMED JOINT CALL for the Strategic International Collaborative Research Program (SICORP). This research was supported by MEXT Promotion of Distinctive Joint Research Center Program Grant Numbers JPMXP0618217493, JPMXP06222717006 at the Advanced Medical Research Center, Yokohama City University. R.I. acknowledges support from Japan Diabetes Foundation. R.N.K. acknowledges support from NIH RO1 DK067536 and in part from RO1 DK129464.

**AUTHOR CONTRIBUTIONS**
J.S. designed the research; R.I., T.T., Y. Togashi, T.O., A.S., K.N., M.K., J.L., S.F., D.M., Y.S., and J.S. performed the experiments. T.K. and AM.J.S. contributed to the human islet preparation. Y.A. and K.F.
contribution to the study for electron microscopy. H.K. and K.B. contributed to the generation of transgenic mice. R.N.K. contributed to the β-cell studies and edited the manuscript. J.S. and R.I. wrote the manuscript, contributed to the discussion, and reviewed and edited the manuscript. R.I., T.T., Y. Togashi, M.K., T.O., Y. Terauchi, and J.S. analyzed the data. R.I., T.T., Y. Togashi, T.O., K.N., M.K., J.L., T.K., D.M., H.K., K.B., AM.J.S., R.N.K., Y. Terauchi, and J.S. revised the manuscript. All authors approved the final version of the manuscript. J.S. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

DECLARATION OF INTERESTS

The authors declare that they have no conflicts of interest.

Received: July 22, 2021
Revised: March 25, 2022
Accepted: June 8, 2022
Published: July 15, 2022

REFERENCES

Alessi, M., Lupi, R., Spannatiato, D., Piro, S., Masini, M., Boggi, U., Del Prato, S., Rabuazzo, A.M., Purrello, F., and Marchetti, P. (2005). Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Diabetologia 48, 282–289.

Assmann, A., Ueki, K., Winnay, J.N., Kadawski, T., and Kulkarni, R.N. (2009). Glucose effects on beta-cell growth and survival require activation of insulin receptors and insulin receptor substrate 2. Mol. Cell Biol. 29, 3219–3228.

Bo, J., Xie, S., Guo, Y., Zhang, C., Guan, Y., Li, C., Lu, J., and Meng, Q.H. (2016). Methyglyoxal impairs insulin secretion of pancreatic β-cells through increased production of ROS and mitochondrial dysfunction mediated by upregulation of UCP2 and MAPKs. J. Diabetes Res. 2016, 2029854.

Brown, J.E., Thomas, S., Digby, J.E., and Dunmore, S.J. (2002). Glucose induces and leptin decreases expression of uncoupling protein-2 mRNA in human islets. FEBs Lett. 513, 189–192.

Brown, M.R., Holmes, H., Rakshit, K., Javeed, N., Her, T.K., Stiller, A.A., Sen, S., Shull, G.E., Prakash, Y.S., Romero, M.F., et al. (2021). Electrogenic sodium bicarbonate cotransporter NBCe1 regulates pancreatic β-cell function in type 2 diabetes. J. Clin. Invest. 131, e142365.

Burkowitz, K., Feng, G., Dutta, S., Kelley, C.A., Steinbaugh, M., Cram, E.J., and Mair, W.B. (2020). Atf-6 regulates Lifspan through ER-mitochondrial calcium homeostasis. Cell Rep. 32, 108125.

Chan, C.B., MacDonald, P.E., Saleh, M.C., Johns, D.C., Marban, E., and Wheeler, M.B. (1999). Overexpression of uncoupling protein 2 inhibits glucose-stimulated insulin secretion from rat islets. Diabetes 48, 1482–1486.

Chandra, V., Holla, P., Ghosh, D., Chakrabarti, D., Padigaru, M., and Jareel, S. (2011). The hepatitis E virus ORF3 protein regulates the expression of liver-specific genes by modulating localization of hepatocyte nuclear factor 4. PLoS One 6, e22412.

Corsi, C.A.S., Pearson, G.L., Renberg, A., Askar, M.M., Vodhekto, I., MacDougald, O.A., and Soleimani, S.A. (2019). The E3 ubiquitin ligase parkin is dispensable for metabolic homeostasis in murine pancreatic β cells and adipocytes. J. Biol. Chem. 294, 7296–7307.

Ekstrand, M.I., Falkenberg, M., Rantanen, A., Park, C.B., Gaspari, M., Hultenby, K., Rustin, P., Gustafsson, C.M., and Larsson, N.G. (2004). Mitochondrial transcription factor A regulates mtDNA copy number in mammals. Hum. Mol. Genet. 13, 935–944.

Frecirekia, M., Blyra, J., Michail, M., Meglasson, M.D., and Nelson, D. (1992). Energy metabolism in islets of Langerhans. Biochim. Biophys. Acta 1101, 273–295.

Fleury, C., Neverova, M., Collins, S., Rainbault, S., Champigny, O., Levy-Meyrueis, C., Boulfaud, A., Seldin, M.F., Survit, R.S., Ricquere, D., et al. (1997). Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat. Genet. 15, 269–276.

Galetti, S., Sarre, A., Perreten, H., Produit-Zengaffinen, N., Muzin, M., and Assimacopoulos-Jeannet, F. (2009). Fatty acids do not activate UCP2 in pancreatic beta cells: comparison with UCP1. Pflugers Arch. 457, 931–940.

Gerbitz, K.D., Gempel, K., and Bidruska, D. (1996). Mitochondria and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit. Diabetes 45, 113–126.

Gerst, F., Jaghutri, B.A., Stagger, H., Schulte, A.M., Lorza-Gille, E., Kaiser, G., Panse, M., Haug, S., Heini, M., and Hirt, M., et al. (2018). The expression of aldolase B in islets is negatively associated with insulin secretion in humans. J. Clin. Endocrinol. Metab. 103, 4373–4383.

Haythome, E., Roth, M., van de Bunt, M., Breton, M.F., Tarasov, A.I., Blacker, T.S., Sachse, G., Silva Dos Santos, M., Terron Exposito, R., Davis, S., et al. (2019). Diabetes causes marked inhibition of mitochondrial metabolism in pancreatic β-cells. Nat. Commun. 10, 2474.

Hechtcohe, H.R., Lee, M.D., Zhang, X., Saunter, C.D., Wilson, C., and McCarron, J.G. (2019). Endothelial TRPV4 channels modulate vascular tone by Ca(2+)-induced Ca(2+)-release at inositol 1,4,5-trisphosphate receptors. Br. J. Pharmacol. 176, 3297–3317.

Hohmeier, H.E., Mulder, H., Chen, G., Henkel-Rieger, R., Preti, M., and Newgard, C.B. (2000). Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49, 424–430.

Holst, J.J. (2007). The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409–1439.

Hong, Y.H., Varanasi, U.S., Yang, W., and Leff, T. (2003). AMP-activated protein kinase regulates HNF4α transcriptional activity by inhibiting dimer formation and decreasing protein stability. J. Biol. Chem. 278, 27495–27501.

Inoue, H., Shirakawa, J., Togashi, Y., Tajima, K., Okumura, T., Kyohara, M., Tanaka, Y., Orina, K., Sashio, Y., Yamada, T., et al. (2018). Signaling between pancreatic β-cells and macrophages via S100 calcium-binding protein A8 exacerbates β-cell apoptosis and islet inflammation. J. Biol. Chem. 293, 5934–5946.

Jiang, P., Ren, L., Zhi, Y., Lu, Z., Lv, F., Feng, W., Bai, X., Cheng, K., Quan, L., et al. (2021). Negative regulation of AMPK signaling by high glucose via E3 ubiquitin ligase MIG53. Mol. Cell 81, 629–637.e5.

Kahn, S.E. (2000). The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am. J. Med. 108, 25–85.

Kang, G., Chepuny, O.G., and Holz, G.G. (2001). cAMP-regulated guanine nucleotide exchange factor (Epac2) mediates Ca2+-induced Ca2+-release in INS-1 pancreatic beta-cells. J. Physiol. 536, 375–385.

Kim, B.J., Park, K.H., Yim, C.Y., Takasawa, S., Okamoto, H., Im, M.J., and Kim, U.H. (2008). Generation of nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose by glucagon-like peptide-1 evokes Ca2+ signal that is essential for insulin secretion in mouse pancreatic islets. Diabetes 57, 868–878.

Koshenov, Z., Offaz, F.E., Hirtl, M., Backhoenig, O.A., Rost, R., Osibow, K., Goktesschalk, B.,
Madreiter-Sokolowski, C.T., Waldecker-Weiermair, M., Malli, R., et al. (2020). The contribution of uncoupling protein 2 to mitochondrial Ca(2+) homeostasis in health and disease - a short revisit. Mitochondrion 35, 164–173.

Krauss, S., Zhang, C.Y., Scorrano, L., Dalgaard, L.T., St-Pierre, J., Grey, S.T., and Lowell, B.B. (2003). Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J. Clin. Invest. 112, 1831–1842.

Kubota, N., Tobe, K., Terauchi, Y., Eto, K., Yamauchi, T., Suzuki, R., Tsubamoto, Y., Komeda, K., Nakano, R., Miki, H., et al. (2000). Disruption of pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96, 329–339.

Kumar, A., Katz, L.S., Schulz, A.M., Kim, M., Honig, L.B., Li, L., Davenport, B., Homann, D., Garcia-Olmeda, A., Herman, M.A., et al. (2018). Activation of Nrf2 is required for normal and drug-induced glucose-stimulated beta-cell proliferation. Diabetes 67, 1561–1575.

Lemasters, J.J., Nieminen, A.L., Qian, T., Tost, L.C., Elmore, S.P., Nishimura, Y., Crowe, R.A., Cascio, W.E., Bradham, C.A., Brenner, D.A., et al. (1998). The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim. Biophys. Acta 1366, 177–196.

Li, M., Zhang, C.S., Zong, Y., Feng, J.W., Ma, T., Hu, M., Lin, Z., Li, X., Xie, C., Wu, Y., et al. (2019). Transient receptor potential V channels are essential for glucose sensing by aldose and AMPK. Cell Metab. 30, 508–524.e12.

Li, N., Brun, T., Cnop, M., Cunha, D.A., Eizirik, G.B., and Herbert, T.P. (2011). PERK activation at low glucose concentration is mediated by SERCA pump inhibition and confers preemptive cyto-protection to pancreatic beta-cells. Mol. Endocrinol. 25, 315–326.

Mamm, T., Yamagata, K., Tanaka, T., Kodama, T., Sladek, F.M., Fukui, K., Katsube, F., Sato, Y., Miyagawa, J., and Shimomura, I. (2008). Expression of HNF-4alpha (MODY1), HNF-1beta (MODY2), and HNF-1alpha (MODY3) proteins in the developing mouse pancreas. Gene Expr. Patterns 8, 96–106.

Narendra, D., Tanaka, A., Suen, D.F., and Yuule, R.J. (2008). Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795–806.

Nederwag, J., Golożubowicz, V., Matthias, A., Acá, A., Jacobsson, A., and Cannon, B. (2001). UCP1: the only protein able to mediate adaptive non-shivering thermogenesis and metabolic inefficiency. Biochem. Biophys. Acta 1504, 82–106.

Nicholls, D.G. (2016). The pancreatic beta-cell: a bioenergetic perspective. Physiol. Rev. 96, 1385–1447.

Nicholls, D.G. (2021). Mitochondrial proton leaks and uncoupling proteins. Biochim. Biophys. Acta Bioenerg. 1862, 148428.

Nolan, C.J., Madiraju, M.S., Delghano-Gregori, Augusto, V., Peyot, M.L., and Pretkis, M. (2006). Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 55, S16–S23.

Palmer, A.E., Jin, C., Reed, J.C., and Tsien, R.Y. (2004). Bcl-2-mediated alterations in endoplasmic reticulum Ca(2+) analyzed with an improved genetically encoded fluorescent sensor. Proc. Natl. Acad. Sci. USA 101, 17404–17409.

Pi, J., Bai, Y., Daniel, K.W., Liu, D., Lyght, O., Edelstein, D., Brownlee, M., Corkey, B.E., and Collins, S. (2009). Persistent oxidative stress due to absence of uncoupling protein 2 associated with impaired pancreatic beta-cell function. Endocrinology 150, 3040–3048.

Produit-Zengaffinen, N., Davis-Lameloise, N., Perreten, H., Becard, D., Gjirovi, A., Keller, P.A., Wollheim, C.B., Herrera, P., Muzzin, P., and Assimacopoulos-Jeannet, F. (2007). Increasing uncoupling protein 2 in pancreatic beta cells does not alter glucose-induced insulin secretion but decreases production of reactive oxygen species. Diabetologia 50, 84–93.

Robson-Doucette, C.A., Sultan, S., Allister, E.M., Wikstrom, J.D., Koskin, V., Bhattacharjee, A., Prentice, K.J., Sereda, S.B., Shirihi, O.S., and Wheeler, M.B. (2011). Beta-cell uncoupling protein 2 regulates reactive oxygen species production, which influences both insulin and glucagon secretion. Diabetes 60, 2710–2719.

Rouset, S., Mozo, J., Dujardin, G., Emre, Y., Masscheley, S., Ricquier, D., and Cassard-Doulcier, A.M. (2007). UCP2 is a mitochondrial transporter with an unusual very short half-life. FEBs Lett. 581, 479–482.

Shirakawa, J., Okuyama, T., Yoshida, E., Shimizu, M., Horigome, Y., Tuno, T., Hayasaka, M., Abe, S., Fuse, M., Togashi, Y., et al. (2011). Protective effects of dipicyclohexylamine-4 (DPA-4) inhibitor against increased beta-cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. J. Biol. Chem. 286, 25467–25476.

Shirakawa, J., Okuyama, T., Yoshida, E., Shimizu, M., Horigome, Y., Tuno, T., Hayasaka, M., Abe, S., Fuse, M., Togashi, Y., et al. (2011). Effects of the antitumor drug OSI-906, a dual inhibitor of IGF-1 receptor and insulin receptor, on the glycemic control, beta-cell functions, and beta-cell proliferation in male mice. Endocrinology 155, 2102–2111.

Shirakawa, J., Togashi, Y., Sakamoto, E., Kaji, M., Tajima, K., Orme, I., Inoue, H., Kubota, N., Kadowaki, T., and Terauchi, Y. (2013). Glucokinease activation ameliorates ER stress-induced apoptosis in pancreatic beta-cells. Diabetes 62, 3448–3458.

Sidara, V., Pearson, G.L., Parekh, V.S., Thompson, B., Christen, L., Gingerich, M.A., Zhu, J., Strome, T., Ren, J., Reck, E.C., et al. (2020). Mitophagy protects β-cells from inflammatory damage in diabetes. JCI Insight 5, e114138.

Taddeo, E.P., Stiles, L., Sereda, S., Ritou, E., Wolf, D.M., Abdullah, M., Swanson, Z., Wilhelm, J., Bellin, M., McDonald, P., et al. (2018). Individual islet respirometry reveals functional diversity within the islet population of mice and human donors. Mol. Metab. 16, 150–159.

Trenker, M., Malli, R., Fertschau, I., Levak-Frank, S., and Graier, W.F. (2007). Uncoupling proteins 2 and 3 are functional for mitochondrial Ca(2+) unimport. Nat. Cell Biol. 9, 445–452.

Urbano, F., Filippello, A., Di Pino, A., Barbagallo, D., Di Mauro, S., Pappalardo, A., Rabuazzo, A.M., Purrello, M., Purrello, F., and Piro, S. (2016). Altered expression of uncoupling protein 2 in GLP-1-producing cells after chronic high glucose exposure: implications for the pathogenesis of diabetes mellitus. Am. J. Physiol. Cell Physiol 310, C558–C567.
Vozza, A., Parisi, G., De Leonardis, F., Lasorsa, F.M., Castegna, A., Amorese, D., Marmo, R., Calcagnile, V.M., Palmieri, L., Ricquier, D., et al. (2014). UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation. Proc. Natl. Acad. Sci. USA 111, 960–965.

Wang, H., Maechler, P., Antinozzi, P.A., Hagenfeldt, K.A., and Wollheim, C.B. (2000). Hepatocyte nuclear factor 4alpha regulates the expression of pancreatic beta-cell genes implicated in glucose metabolism and nutrient-induced insulin secretion. J. Biol. Chem. 275, 35953–35959.

Yagishita, Y., Fukutomi, T., Sugawara, A., Kawamura, H., Takahashi, T., Pi, J., Uruno, A., and Yamamoto, M. (2014). Nrf2 protects pancreatic beta-cells from oxidative and nitrosative stress in diabetic model mice. Diabetes 63, 605–618.

Yamada, H., Yoshida, M., Ito, K., Dezaki, K., Yada, T., Ishikawa, S.E., and Kakei, M. (2016). Potentiation of glucose-stimulated insulin secretion by the GPR40-PLC-TRPC pathway in pancreatic beta-cells. Sci. Rep. 6, 25912.

Zhang, C.Y., Baffy, G., Perret, P., Krauss, S., Peroni, O., Grujic, D., Hagen, T., Vidal-Puig, A.J., Boss, O., Kim, Y.B., et al. (2001). Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 105, 745–755.

Zhang, C.Y., Parton, L.E., Ye, C.P., Krauss, S., Shen, R., Lin, C.T., Porco, J.A., Jr., and Lowell, B.B. (2006). Genipin inhibits UCP2-mediated proton leak and acutely reverses obesity- and high glucose-induced beta cell dysfunction in isolated pancreatic islets. Cell Metab. 3, 417–427.

Zhang, Y., Xie, Z., Zhou, G., Zhang, H., Lu, J., and Zhang, W.J. (2010). Fructose-1,6-bisphosphatase regulates glucose-stimulated insulin secretion of mouse pancreatic beta-cells. Endocrinology 151, 4688–4695.

Zizkova, P., Viskupicova, J., Heger, V., Rackova, L., Majekova, M., and Horakova, L. (2018). Dysfunction of SERCA pumps as novel mechanism of methylglyoxal cytotoxicity. Cell Calcium 74, 112–122.

Zorzano, A., Liesa, M., Sebastian, D., Segales, J., and Palacin, M. (2010). Mitochondrial fusion proteins: dual regulators of morphology and metabolism. Semin. Cell Dev. Biol. 21, 566–574.
### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Antibodies          |        |            |
| Alpha Tubulin antibody[DM1A] | Abcam  | Cat# ab7291; RRID: AB_2241126 |
| Anti-beta Actin antibody | Abcam  | Cat# ab8227; RRID: AB_2305186 |
| UCP2 (T1OSV) Rabbit mAb | Cell Signaling Technology | Cat# 89326; RRID: AB_2721818 |
| UCP2 (C-20) antibody | Santa Cruz Biotechnology  | Cat# sc-6525; RRID: AB_2213585 |
| UCP2 Polyclonal antibody | Proteintech | Cat# 11081-1-AP; RRID: AB_2213793 |
| ALDOB antibody | Proteintech  | Cat# 18065-1-AP; RRID: AB_2273968 |
| PARK1 antibody | Abcam  | Cat# ab23707; RRID: AB_447627 |
| Parkin (PRKB) antibody | Santa Cruz Biotechnology | Cat# sc-32282; RRID: AB_628104 |
| VDAC antibody | Cell Signaling Technology  | Cat# 4866; RRID: AB_2272627 |
| Total OXPHOS Rodent WB Antibody Cocktail | Abcam  | Cat# ab110413; RRID: AB_2629281 |
| SOD2 antibody | Proteintech  | Cat# 24127-1-AP; RRID: AB_2879437 |
| NRF2 antibody | Proteintech  | Cat# 16396-1-AP; RRID: AB_2879437 |
| NRF2 antibody | Proteintech  | Cat# 16396-1-AP; RRID: AB_2879437 |
| HNF4-alpha antibody | Abcam  | Cat# ab201460; RRID: N/A |
| Insulin (H-86) antibody | Santa Cruz Biotechnology  | Cat# sc-9168; RRID: AB_2126540 |
| anti-bromodeoxyuridine, anti-BrdU antibody | Dako  | Cat# M0744; RRID: AB_10013660 |
| Guinea Pig Anti-insulin Polyclonal Antibody | Abcam  | Cat# ab7842; RRID: AB_306130 |
| Donkey Anti-Goat IgG H&L (Alexa Fluor® 488) | Abcam  | Cat# ab150129; RRID: AB_2687506 |
| Donkey anti-Goat IgG (H + L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 647 | Invitrogen | Cat# A-21447; RRID: AB_141844 |
| Alexa Fluor® 594 AfiniPure Donkey Anti-Guinea Pig IgG (H + L) | Jackson ImmunoResearch | Cat# 706-585-148; RRID: AB_2340474 |
| Donkey anti-Rabbit IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 | Invitrogen | Cat# A-21206; RRID: AB_141708 |
| Donkey anti-Rabbit IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 555 | Invitrogen | Cat# A-31572; RRID: AB_162543 |
| Bacterial and virus strains | VECTOR BIOLABS | Cat# shADV-252486 |
| Ad-GFP-U6-m-ALDOB-shRNA | VECTOR BIOLABS | Cat# shADV-252486 |

**Biological samples**

- Human islets, see Table S1: Alberta Islet Distribution Program and Islet Core [https://www.epicore.ualberta.ca/isletcore/](https://www.epicore.ualberta.ca/isletcore/)

**Chemicals, peptides, and recombinant proteins**

- RPMI 1640(No Glucose) with L-Gln, liquid: Nacalai tesque, Kyoto, Japan | Cat# 09892-15
- DMEM(No Glucose) with L-Gln, without Sodium Pyruvate, liquid: Nacalai tesque, Kyoto, Japan | Cat# 09891-25
- Agilent Seahorse XF RPMI Medium (without Phenol Red): Agilent Technologies | Cat# 103336-100
- HBSS(+ with Ca, Mg, without Phenol Red, liquid: Nacalai tesque, Kyoto, Japan | Cat# 09735-75
- HBSS(-) without Ca, Mg and Phenol Red, liquid: Nacalai tesque, Kyoto, Japan | Cat# 17461-05

(Continued on next page)
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| D-PBS(-) without Ca and Mg, liquid | Nacalai tesque, Kyoto, Japan | Cat# 14249-95 |
| Final Wash/Culture Medium | Mediatech | Cat# 99-785-CV |
| 45(w/v)%-D-(+)-Glucose Solution | Nacalai tesque, Kyoto, Japan | Cat# G8769 |
| 100mM-Sodium Pyruvate Solution(100x) | Nacalai tesque, Kyoto, Japan | Cat# 06977-34 |
| Penicillin-Streptomycin Mixed Solution | Nacalai tesque, Kyoto, Japan | Cat# 26253-84 |
| 200mmol/l L-Alanyl-L-glutamine Solution(100x) | Nacalai tesque, Kyoto, Japan | Cat# 04260-64 |
| 1mol/L-HEPES Buffer Solution | Nacalai tesque, Kyoto, Japan | Cat# 17557-94 |
| 2-Mercaptoethanol | Nacalai tesque, Kyoto, Japan | Cat# 21417-52 |
| 5-Bromo-2'-deoxyuridine | Nacalai tesque, Kyoto, Japan | Cat# 05650-66 |
| Poly-L-lysine solution | Sigma-Aldrich | Cat# P4707 |
| Protease Inhibitor Cocktail(EDTA free) (100x) | Nacalai tesque, Kyoto, Japan | Cat# 03969-21 |
| Phosphatase Inhibitor Cocktail(EDTA free) (100x) | Nacalai tesque, Kyoto, Japan | Cat# 07575-51 |
| SYBR® Green Supermix | Bio-Rad | Cat# 1725274 |
| METAFACTENE® PRO | Biontex | Cat# T040 |
| Glucokinase Activator, CpdA | Calbiochem | Cat# 346021 |
| Insulin solution human | Sigma-Aldrich | Cat# I9278 |
| Humulin R | Eli Lilly | HI-210 |
| N-acetyl-L-cysteine cell culture tested | Sigma-Aldrich | Cat# A9165 |
| Sodium palmitate | Sigma-Aldrich | Cat# P9767 |
| Thapsigargin | Sigma-Aldrich | Cat# T9033 |
| Rapamycin | Calbiochem | Cat# 553210 |
| Diazoxide | Wako Pure Chemical Industries | Cat# 364-98-7 |
| Nifedipin | Sigma-Aldrich | Cat# N7634 |
| FK-506 | Sigma-Aldrich | Cat# F4679 |
| Akt Inhibitor X | Calbiochem | Cat# 124020 |
| U0126 | Cell Signaling Technology | Cat# 99035 |
| OSI-906 | Selleck Chemicals | Cat# S1091 |
| Liraglutide | Novo Nordisk | N/A |
| Genipin | Wako Pure Chemical Industries | Cat# 078-03021 |
| HC-067047 | Santa Cruz Biotechnology | Cat# sc-361204 |
| TAK-875 (Fasiglifam) | AdooQ Bio Science | Cat# A11018 |
| DAPI solution | Wako Pure Chemical Industries | Cat# 340-07971 |
| Opti-MEM™ | Thermo Fisher Scientific | Cat# 31985062 |
| Fluoro-KEEPER Antifade Reagent, Non-Hardening Type | Nacalai tesque, Kyoto, Japan | Cat# 12593-64 |
| ProLong™ Gold Antifade Mountant | Invitrogen | Cat# P10144 |
| No.15HT(0.17 ± 0.005mm) cover glass | MATSUNAMI | N/A |
| No.1(0.13–0.17mm) cover glass | MATSUNAMI | Cat# C024241 |
| Fluo-8®, AM | AAT bioquest | Cat# 21081 |
| EGTA | Wako Pure Chemical Industries | Cat# 348-01311 |

Critical commercial assays

| Ultra Sensitive Mouse Insulin ELISA Kit | Morinaga Institute of Biological Science, Yokohama, Japan | Cat# MS303 |
| Ultra Sensitive Human Insulin ELISA Kit | Mercodia | Cat# 10-1132-01 |
| Methylglyoxal colorimetric assay kit | Bio Vision | Cat# K500-100 |

(Continued on next page)
### REAGENT or RESOURCE SOURCE IDENTIFIER

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Glutest Neo Super   | Sanwa Chemical Co. Kanagawa, Japan | N/A |
| Protein Assay BCA Kit | Nacalai tesque, Kyoto, Japan | Cat# 06385-00 |
| RNase Mini Kit      | QIAGEN | Cat# 74106 |
| High-Capacity cDNA Reverse Transcription Kit | Thermo Fisher Scientific | Cat# 4368813 |
| ADP/ATP Ratio Assay Kit | Abcam | Cat# ab65313 |
| VECTASTAIN® Elite® ABC HRP Kit | Vector Laboratories | Cat# PK-6101 |
| DAB Peroxidase (HRP) Substrate Kit | Vector Laboratories | Cat# V49320 |
| pAd/CMV/V5-DEST™ Gateway™ Vector Kit | Invitrogen | Cat# K240020 |
| Seahorse XFe96 Flux Pak | Agilent Technologies | Cat# 102416-100 |
| Seahorse XF Mito Stress Kit | Agilent Technologies | Cat# 103015-100 |
| Mitophagy Detection Kit | Dojindo Molecular Technologies | Cat# M0D1 |
| MT-1 MitoMP Detection Kit | Dojindo Molecular Technologies | Cat# MT13 |
| mtSOX Deep Red –Mitochondrial Superoxide Detection kit | Dojindo Molecular Technologies | Cat# MT14 |

### Deposited data

- **Gene expression profiling in islets from bUCP2Tg mice by array**
  This paper
  GSE147269, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147269

### Experimental models: Cell lines

| Cell line | Laboratory | Accession No. |
|-----------|------------|---------------|
| Control b-cells | Laboratory of R.N. Kulkarni (Assmann et al., 2009; Kulkarni et al., 1999) | N/A |
| IRS2KO b-cells | Laboratory of R.N. Kulkarni (Assmann et al., 2009; Kulkarni et al., 1999) | N/A |
| MIN6-m9 b-cells | Laboratory of Susumu Seino (Minami et al., 2000) | N/A |
| INS1 832/13 b-cells | Laboratory of Christopher Newgard (Hohmeier et al., 2000) | N/A |

### Experimental models: Organisms/strains

- **bUCP2Tg mice**
  This paper
  Referred to as RIP-UCP-2: Accession No. CDB0543T: http://www2.clst.riken.jp/arg/micelist.html

- **Mouse: BKS.Cg-Dock7m+/+Leprdb/J**
  Charles River Japan
  https://www.crj.co.jp/product/rm/detail/db

- **Mouse: IRS-2-/-mice**
  Kubota et al. (2000)
  N/A

### Oligonucleotides

- **Primers for qPCR, see Table S2**
  This paper
  N/A

### Recombinant DNA

- **Plasmid: Aldob Mouse tagged Clone**
  ORIGENE
  Cat# MR205585

- **Plasmid: UCP2 Mouse Untagged Clone**
  ORIGENE
  Cat# MC205697

- **Plasmid: pcDNA-D1ER**
  Addgene
  Cat# 36325; RRID: Addgene_36325

### Software and algorithms

- **ImageJ software**
  NIH
  https://imagej.nih.gov/ij/

- **Prism 8 software**
  Graph Pad Software
  https://www.graphpad.com/scientific-software/prism/

- **Image LabTM software**
  Bio-Rad
  https://www.bio-rad.com/
RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jun Shirakawa MD PhD. (jshira@gunma-u.ac.jp).

Materials availability
βUCP2Tg mouse lines in this study have been deposited at CDB database (referred to as RIP-UCP-2: Accession No. CDB0543T: http://www2.clst.riken.jp/arg/micelist.html).

Data and code availability
Microarray data for βUCP2Tg islets have been deposited at GEO. Accession number is GSE147269. The microarray data can be found at GEO: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147269. This paper does not report original code.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mice
βUCP2Tg mice (referred to as RIP-UCP-2: Accession No. CDB0543T: http://www2.clst.riken.jp/arg/micelist.html) were generated as follows. A mouse UCP2 cDNA clone was obtained from Origene (#MC205697). The transgene consisted of 801 bp of the rat Ins2 promoter linked to an intron sequence of rabbit β-globin, the Ucp2 cDNA and a polyadenylation sequence. The purified 2.9-kb fragment digested with Not1 was micro-injected into fertilized eggs. The primers used for genotyping PCR were as follows: forward primer: 5′-CATCCTGCCTTTCTCTTTATGG-3′, reverse primer: 5′-AGGAACCTTCACAGTGCTTG-3′. The mice were backcrossed with C57BL6/J mice more than 10 times. 8- to 20-week-old male βUCP2Tg mice and their littermate wild-type (WT) mice were used in all experiments. Male BKS.Cg-Dock7m+/+Leprdb/J (db/db) and their controls (db/+) were obtained from Charles River Japan (Yokohama, Japan). Male insulin receptor substrate (Irs)-2-deficient (IRS2KO) mice (Kubota et al., 2000) and db/db mice were used for the islet study.
and those mice were 9-11 weeks old. All mice were housed under a 12-hour light-dark cycle. This study was conducted with the approval of the Animal Care Committee of Yokohama City University ( Permit No. F-A-16-055) and Gunma University (Permit No. 21-031). All animal procedures were performed in accordance with the institutional animal care guidelines and the guidelines of the Animal Care Committee of Yokohama City University and Gunma University.

Cell lines and adenovirus
β-cell lines from male control or IRS2KO mice, INS1 832/13 cells, and MIN6-M9 cells have been described previously (Assmann et al., 2009; Hohmeier et al., 2000; Kulkarni et al., 1999; Minami et al., 2000). β-cell lines from control and IRS2KO mice were used for qPCR experiments and maintained in high-glucose (25 mmol/L) DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. INS1 832/13 cells were used for western blot and intracellular Ca2+ assay, and maintained in RPMI1640 containing 11.1 mmol/L glucose, 10% FBS and 1% penicillin/streptomycin. MIN6-M9 cells were maintained in high-glucose (25 mmol/L) DMEM supplemented with 10% FBS and 1% penicillin/streptomycin and used for the experiments of qPCR, western blot, insulin secretion assay, mitochondrial membrane potential, mitochondrial oxidative stress and immunostaining. In all experiments, cells were incubated at 37°C. Adenoviruses containing Ucp2, AldB, or LacZ were generated using the Virapower adenoviral expression system (Invitrogen, Switzerland) as described elsewhere (Inoue et al., 2018). Sh-RNA for mouse AldB and scramble control were purchased from VECTOR BIOLABS (USA). The sequence of shRNA was as follows. Sh-AldB: 5’-CCGGGTGAGGAGGATGCTACACTTA-CTCGAG-TAAGTGTAGCATCCTCCTCAC-TTTTTG-3’. Sh-Scramble: 5’-GATCC-AGTACTGC TTACGATACGG-TTCAAGAGACCGTATCGTAAGCAGTAC-TTTTTTT-3’.

Human islet studies
Human islets were obtained from the Alberta Islet Distribution Program and Islet Core. The details of the human islets are described in Table S1. Upon receipt, the islets were cultured overnight in Miami Medium #1A (Mediatech, USA) and then cultured in Final Wash/Culture Medium (Mediatech). Human islets were cultured at 37°C in a CO2 incubator. For the immunostaining experiments, human islets were cultured in the presence of 5.6 mmol/L or 16.7 mmol/L glucose for 48 h and then embedded in agarose. For the GSIS and qPCR study, human islets were infected with Ad-LacZ or Ad-Ucp2 at 3×10^6 MOI for 48 h and then treated with glucose in Krebs-Ringer bicarbonate (KRB) buffer medium. The insulin concentration in KRB buffer and insulin content of islets were measured by using a human insulin ELISA kit (Mercodia, Sweden). All the studies and protocols for human islets were approved by the Yokohama City University Ethics Board (approval B171100025) and Gunma University Ethics Board (approval HS2020-174).

METHOD DETAILS

Immunoblotting and Abby western protein analysis
Mouse islets or cells were solubilized in lysis buffer with protease inhibitors (Nacalai Tesque) and phosphatase inhibitors (Nacalai Tesque). The protein concentration was measured using a BCA Protein Assay Kit (Nacalai Tesque). After SDS-PAGE at 30 mA for 1 h, proteins were transferred to PVDF membrane (Millipore) using Trans-Blot Turbo (25V-1.0A; Bio-Rad) for 30 min. Immunoblotting was performed with following antibodies. Antibodies against VDAC (#4866) and UCP2 (#89326) were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies against β-tubulin (ab7291), β-actin (ab8227), PINK1 (ab23707), HNF4α (ab201460) and total OXPHOS (ab110413) were purchased from Abcam (Cambridge, MA, USA). Antibodies against UCP2 (sc-6525) and PARKIN (sc-32282) were purchased from Santa Cruz (TX, USA). The antibodies against UCP2 (11081-1-AP), ALDOB (18065-1-AP), NFR2 (16396-1-AP) and SOD2 (24127-1-AP) were purchased from Proteintech (Rosemont, USA). Densitometry was performed using Image Lab™ software (Bio–Rad, Hercules, CA, USA). Automated quantitative western blotting was performed by Abby (ProteinSimple, San Jose, CA) according to the manufacturer’s instructions. Antibodies to the following proteins were used for the analysis of Abby: UCP2 (1:50 dilution; Proteintech, #11081-1-AP) and α-tubulin (1:50 dilution; Abcam, #ab7291). Default assay parameters were used for control and data analysis and peak areas were calculated using the Compass software (ProteinSimple).

qPCR and microarray analysis
Total RNA was isolated from handpicked islets, livers and hypothalamus using an RNase-free DNase and RNeasy Kit (Qiagen, Valencia, CA). The concentration of total RNA was measured by a NanoDrop One (Applied Biosystems). It was confirmed that the A260/A280 ratio was 1.8–2.1 and the A260/A230 ratio.
was more than 2.0 in extracted total RNA. cDNA was prepared using High Capacity cDNA Reverse Transcription Kits (Applied Biosystems) and was subjected to qPCR quantitative PCR using Sybr Green Gene Expression Assays (7900 Real-Time PCR System; Applied Biosystems) with THUNDERBIRD qPCR Master Mix (TOYOBO). The primers are listed in Table S2. A DNA microarray was performed using an Agilent-074809 Sure Print G3 Mouse GE8 × 60K Microarray (GPL21163) (Agilent, Santa Clara, CA, USA). The quality of total RNA was measured by a Bioanalyzer (Agilent), and the samples showing an RNA integrity number (RIN) of 7.0 or higher were used for microarray analysis. Data were analyzed using Genespring GX software (Agilent). The microarray data can be found at GEO: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147269.

Immunostaining studies
Pancreatic tissue sections from UCP2Tg mice and in vitro-cultured human islets were immunostained with anti-insulin (Abcam), anti-UCP2 (Santa Cruz), anti-AldB (Proteintech), or anti-BrdU (Dako, Tokyo, Japan) antibodies. Images were acquired as described elsewhere (Shirakawa et al., 2013). For immunofluorescence cytochemistry (IFCC), 1 × 10⁴ MIN6-M9 cells were seeded on poly-L-lysine-coated chamber slides (Nunk, #154334PK) and infected with Ad-LacZ or Ad-Ucp2 at an MOI of 500 for 48 h. Cells were fixed with 4% PFA and were permeabilized with 0.01% Triton X-100 in PBS. Anti-HNF4α antibody was purchased from Abcam (#ab201460). Images were acquired using an FV1000-D confocal laser scanning microscope (Olympus, Japan). Super resolution STED microscopic images were acquired using TCS SP8 STED (Leica Microsystems, Germany).

Electron microscopy
Isolated islets were fixed in a mixture of 2% glutaraldehyde and 1% OsO₄ in 0.1 mol/L phosphoric acid buffer. Islets were embedded in epoxy resin, and the blocks were trimmed with a diamond knife. Images from ultrathin sections were acquired with an HT-7500 electron microscope (Hitachi, Tokyo, Japan).

Mouse studies
Blood glucose and serum insulin levels were determined using Glutest Neo Super (Sanwa Chemical Co. Kanagawa, Japan) and an insulin ELISA kit (Morinaga Institute of Biological Science, Yokohama, Japan), respectively. For the oral glucose tolerance test (OGTT), all mice were denied access to food for 16–20 h before the OGTT. The insulin tolerance test (ITT) was performed by intraperitoneal injection of human insulin (0.75 mU/g body weight).

Islet studies
Islets were isolated from 8- to 12-week-old mice as described elsewhere (Shirakawa et al., 2011). Islets were handpicked and cultured overnight in RPMI1640 medium containing 5.6 mmol/L glucose supplemented with 10% FBS (vol./vol.) and penicillin/streptomycin (1% vol/vol). Islets were treated with 30 μmol/L glucose-kinase activator CpdA (GKA, Calbiochem, USA), 20 mmol/l N-acetyl-L-cysteine (Sigma–Aldrich, Switzerland), 50 μmol/L nifedipine (Sigma–Aldrich), 10 μmol/L FK506 (Sigma–Aldrich), 200 μmol/L dioxao-side (Wako Pure Chemical Industries), 200 μmol/L OSI-906 (Selleck Chemicals, USA), 4 μmol/L Akt inhibitor X (Calbiochem), 10 μmol/L U0126 (Selleck Chemicals), 1 μmol/L thapsigargin (Sigma–Aldrich), 5 μmol/L genipin (Wako Pure Chemical Industries, Japan) or 30 nmol/L rapamycin (Calbiochem) for 24 h. For the study related to stimulation with insulin (Sigma–Aldrich), islets were subjected to 6 h of fasting in RPMI1640 medium containing 2.8 mmol/L glucose and 0.1% BSA (vol/vol). ATP contents in mouse islets were measured using the ADP/ATP assay kit (Abcam). Glucose-stimulated insulin secretion (GSIS) from mouse and human islets was induced as described previously (Shirakawa et al., 2011). Insulin secretion data were corrected by the insulin content of islets. One hundred nmol/l liraglutide (Novo Nordisk, Denmark), 5 μmol/L genipin (Wako Pure Chemical Industries, Japan), 10 μmol/L TAK-875 (Fasiglifam, AdooQ BioScienc, USA) or 100 nmol/L HC 067047 (Santa Cruz) were used for the mouse GSIS assay.

Mitochondrial respiration in islets
Mitochondrial respiration in mouse islets was measured according to a previous report (Taddeo et al., 2018). Briefly, isolated islets (20/well) from UCP2Tg mice and WT mice or islets infected with adenoviral vectors were incubated using a culture insert for 24 h in RPMI1640 medium containing 5.6 mmol/L glucose, 1 mmol/L pyruvate (Nacalai Tesque) and 10% FBS. The islets were then washed with PBS (−) and seeded onto poly-L-lysine (Sigma)-coated XF96 cell culture microplates (Agilent Technologies) containing
160 μL/well of the assay medium. The culture microplates were then centrifuged at 500 rpm for 7 min at room temperature and incubated for 1–2 h at 37°C in a non-CO2 incubator. XF RPMI Medium (Agilent Technologies) containing 5.6 mmol/L glucose, 1 mmol/L pyruvate and 2 mmol/L L-glutamine (Nacalai Tesque) was used as the assay medium. The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured using a Seahorse XF96 Analyzer (Agilent Technologies). Basal respiration was measured for 18 min. Then, the islets were sequentially exposed to glucose (11.1 mmol/L final concentration), oligomycin (4 μmol/L final concentration), FCCP (1 μmol/L final concentration) and rotenone/antimycin A (2.5 μmol/L final concentration) for 30 min. Wave 2.6.0 (Agilent Technologies) software was used to analyze the NonMitochondrial Oxygen Consumption, Basal Respiration, Maximal Respiration, Proton Leak, ATP Production, and Spare Respiratory Capacity.

Assay of mitochondrial membrane potential, mitophagy flux and oxidative stress
Mitochondrial membrane potential, mitophagy flux and oxidative stress in MIN6-M9 cells were analyzed using the MT-1 MitoMP Detection Kit (#MT13), Mitophagy Detection Kit (#MD01) and mtSOX Deep Red Mitochondrial Superoxide Detection kit (#MT14) (Dojindo Laboratories, Kumamoto, Japan), respectively. Cells were treated according to the manufacturer’s recommendations. Images were acquired using a BZ-X800 microscope (Keyence).

Methylglyoxal assay in mouse islets
The methylglyoxal concentration in UCP2Tg and WT islets was determined using a methylglyoxal colorimetric assay kit (#K500-100, BioVision) according to the manufacturer’s instructions. One hundred islets were lysed in 50 μL of 0.1% Triton X-100 in PBS, and 20 μL was used to measure the methylglyoxal concentration.

Intracellular Ca2+ measurement
For the mouse islet study, islets were incubated with 5 μmol/L Fluo-8 (AAT Bioquest) for 40 min and then transferred to poly-L-lysine-coated glass-bottom dishes containing Hanks’ balanced salt solution (HBSS). For the fasiglifam stimulation experiment, Ca2+ free HBSS containing 2.8 mmol/L glucose supplemented with 0.1 mmol/L EGTA, 200 μmol/L diazoxide and 50 μmol/L nifedipine was used. Images were acquired using a BZ-X800 microscope (Keyence). For INS1 cells, 2.5 × 10^4 cells were seeded on 96-well plates and infected with Ad-LacZ + Sh-Scramble, Ad-Ucp2 + Sh-Scramble or Ad-Ucp2 + Sh-AldB at an MOI of 10 in the presence of 11.1 mmol/L glucose for 48 h. INS1 cells were incubated in HBSS containing 2.8 mmol/L glucose and 5 μmol/L Fluo-8 and then washed twice with HBSS. The Fluo-8 intensity in the cells was measured every 5 s for 180 s by using an EnSpire Multimode Plate Reader (Parker Elmer). Cells were stimulated with 25 mmol/L glucose HBSS at 30 s. To measure ER Ca2+ in INS1 cells, we used the D1ER plasmid (Palmer et al., 2004). pcDNA-D1ER was a gift from Amy Palmer & Roger Tsien (Addgene plasmid # 36325; http://n2t.net/edggene_36325; RRID:Addgene_36325). A total of 2.5 × 10^4 INS1 cells were seeded on 96-well plates and infected with Ad-LacZ or Ad-Ucp2 at an MOI of 10 in the presence of 11.1 mmol/L glucose for 48 h. D1ER plasmid (0.1 μg) was transfected into cells by using METAFACTENE PRO (Biontex, Germany) 24 h before the Ca2+ assay. Two hours prior to measurement, the medium was changed to HBSS containing 2.8 mmol/L glucose. The intensity of the D1ER was measured every 5 s by an EnSpire Multimode Plate Reader (Parker Elmer). Then, 25 mmol/L glucose was added at 30 s, and 10 μmol/L fasiglifam was added at 180 s. Fluorescence measurements were made using the following wavelengths: Fluo-8 excitation at 490 nm with emission at 525 nm, D1ER excitation at 440 nm with emission at 485 nm.

QUANTIFICATION AND STATISTICAL ANALYSIS
All the data are expressed as the means ± SEM. One-way ANOVA with post hoc analysis was used to compare the values among the different experimental groups. When only two groups were compared, a two-tailed Student’s t test was used. For ANOVA, the homogeneity of variance was tested by Levene’s test. If the results were similar, Tukey’s test or Bonferroni’s test was performed, and if not, Dunnett’s test was adopted. For the two-tailed Student’s t test, variances between two groups were compared by the F test. Prism 8 (GraphPad Software, San Diego, CA, USA) and SPSS software (IBM, Armonk, NY, USA) were used for all statistical analyses. Differences were considered significant if the p value was <0.05 (*) or <0.01 (**).